HYAL1 and neoplasm: Lastly, after confirming HA reduction in all three cell lines, we assessed its impact on tumor volume, CD44 (HA’s main receptor and potential BRCA regulator), HYAL1 (which responds to HA changes), and BRCA1/2 expression.